Brain cancer treatment pioneer sets sights on €5m funding

Spanish biotech KeyZell is aiming for €5m in funding to conduct a human clinical trial for its novel brain cancer treatment.

Based on company founder Dr.Nabil Hajji’s research on cellular apoptosis induced by cell receptor blockage, the start-up will also use the investment to improve its AI system to personalise treatment for each cancer patient.

Collaborating with peers from the universities of Seville and Harvard, Hajji has succeeded in eliminating the most aggressive brain cancer, glioblastoma, following 20 years with no advances in this field.

Having earlier secured €450k in a private placement, KeyZell plans to finance the primary clinical trial in Australia with a further one in Mexico. The firm is also in negotiation with regulators in Europe, US, UK, Thailand, South Africa, Morocco and Canada.

CEO Jose del Coral says: “We created KeyZell with the objective of developing new cancer solutions and tools that can help both medical professionals and patients in their fight against this disease. This financing round will allow us to achieve our ambitious objective.”